Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neonatal perifascicular myopathy

Y Nevo1, A Pestronk

  • 1Department of Neurology, Barnes and St. Louis Children's Hospitals, Washington University School of Medicine, MO 63110, USA.

Pediatric Neurology
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of "critical lesions" on outcomes following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2021
Same author

Evaluation of the IceTag leg sensor and its derivative models to predict behaviour, using beef cattle on rangeland.

Journal of neuroscience methods·2017
Same author

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Journal of neurology, neurosurgery, and psychiatry·2015
Same author

Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A.

Cell death & disease·2015
Same author

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy.

Neurology·2012
Same author

Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Neurology·2012
Same journal

Association of Cerebrospinal Fluid-Restricted Oligoclonal Bands With Relapsing Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Pediatric neurology·2026
Same journal

Variable Phenotype in Three Siblings With RAN Binding Protein 2 Variant With Potential Preventive Treatment for Recurrences.

Pediatric neurology·2026
Same journal

Corrigendum to Temporary Pacemaker in a Pediatric Guillain-Barré Case With Life-Threatening Bradyarrhythmia Pediatr Neurol 177 (2026) 109-110. doi: 10.1016/j.pediatrneurol.2026.01.015.

Pediatric neurology·2026
Same journal

Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease).

Pediatric neurology·2026
Same journal

Examining Epilepsy in Angelman Syndrome: Insights From Caregiver-Reported Data in the Linking Angelman and Dup15q Data for Expanded Research Database.

Pediatric neurology·2026
Same journal

Impact of Postpandemic Pediatric Infection Rebound on Febrile Seizures: A Nationwide Cohort Study, 2013-2023.

Pediatric neurology·2026
See all related articles

Perifascicular atrophy in infants with hypotonia is not always dermatomyositis. Muscle weakness may improve without immunosuppressive therapy, challenging diagnostic assumptions.

Area of Science:

  • Neurology
  • Pediatrics
  • Pathology

Background:

  • Perifascicular atrophy is a hallmark of autoimmune myopathies, especially dermatomyositis.
  • Infantile hypotonia and weakness warrant thorough investigation for underlying causes.

Observation:

  • A neonate presented with hypotonia and muscle weakness.
  • Muscle biopsy showed perifascicular atrophy and regeneration.
  • Abnormal alkaline phosphatase activity was noted in the perimysial connective tissue.

Findings:

  • The infant's weakness was nonprogressive and showed improvement over time.
  • No long-term immunosuppressive therapy was administered.
  • Histopathological findings mimicked those seen in dermatomyositis.

Related Experiment Videos

Implications:

  • Perifascicular myopathic changes in infants do not automatically confirm progressive dermatomyositis.
  • These findings alone are not sufficient to warrant immunosuppressive therapy in neonates.
  • Further investigation is needed to differentiate benign conditions from autoimmune myopathies in infants.